Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Infectious disease

First long-acting HIV therapy approved in US

by Megha Satyanarayana
January 30, 2021 | A version of this story appeared in Volume 99, Issue 4

 

The structure of cabotegravir.

The US Food and Drug Administration has approved Cabenuva, the first long-acting antiviral treatment for HIV. Cabenuva is made of two medications, ViiV Healthcare’s cabotegravir and Janssen Pharmaceuticals’ rilpivirine, which are given once per month by injection. Experts previously told C&EN that long-acting injectables were developed as a matter of convenience, since the alternative for people living with HIV is taking pills every day. ViiV will start shipping the drug in February.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.